Predicting Lung Cancer Response to EGFR Inhibitors
Author Information
Author(s): Balko Justin M, Potti Anil, Saunders Christopher, Stromberg Arnold, Haura Eric B, Black Esther P
Primary Institution: University of Kentucky
Hypothesis
A multivariate predictor of EGFR TKI sensitivity based on gene expression data would offer a clinically useful method of accounting for variability in predicting response to EGFR TKI.
Conclusion
Multivariate predictors of response to EGFR TKI have potential for clinical use and provide a robust predictor of EGFR TKI sensitivity.
Supporting Evidence
- Gene expression data from sensitive and resistant lung cancer cell lines were analyzed to identify predictive patterns.
- Diagonal linear discriminant analysis was used to classify cell lines and human tumors based on their sensitivity to EGFR inhibitors.
- The predictive model demonstrated a 0% misclassification rate in leave-one-out cross-validation.
Takeaway
Scientists created a special test to help doctors know which lung cancer patients will respond to a specific treatment, making it easier to choose the right medicine.
Methodology
The study used gene expression data from lung cancer cell lines and human tumors to develop predictive models for EGFR TKI sensitivity, employing diagonal linear discriminant analysis for classification.
Potential Biases
Potential bias due to unequal replicates used in the model and the reliance on specific cell line types for training.
Limitations
The study's predictive model may not account for all factors influencing EGFR TKI sensitivity, such as pharmacokinetic variability and markers of epithelial to mesenchymal transition.
Participant Demographics
The study involved lung cancer cell lines and human adenocarcinoma tumors, but specific demographic details of human participants were not provided.
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website